Cited by 1,147Multiple Myeloma Research and TreatmentsBone health and treatmentsProtein Degradation and Inhibitors

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Open access

McCarthy, Philip L., Owzar, Kouros, Hofmeister, Craig C., Hurd, David D., Hassoun, Hani, Richardson, Paul G., Giralt, Sergio, Stadtmauer, Edward A., Weisdorf, Daniel J., Vij, Ravi, Moreb, Jan S., Callander, Natalie Scott, Van Besien, Koen, Gentile, Teresa, Isola, Luis, Maziarz, Richard T., Gabriel, Don A., Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H., Levitan, Denise, McClune, Brian, Schlossman, Robert, Hars, Vera, Postiglione, John, Jiang, Chen, Bennett, Elizabeth, Barry, Susan, Bressler, Linda, Kelly, Michael, Seiler, Michele, Rosenbaum, Cara, Hari, Parameswaran, Pasquini, Marcelo C., Horowitz, Mary M., Shea, Thomas C., Devine, Steven M., Anderson, Kenneth C., Linker, Charles·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1114083PMC PMC3744390

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. METHODS: Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). RESULTS: The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 35 patients who received lenalidomide (15%) and 53 patients who received placebo (23%) died (P=0.03). More grade 3 or 4 hematologic adverse events and grade 3 nonhematologic adverse events occurred in patients who received lenalidomide (P<0.001 for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%). CONCLUSIONS: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00114101.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1114083

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Analysis of Survival Data
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,269
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citation
Multiple Myeloma
Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Self-citation
The Statistical Analysis of Failure Time Data
Klein, J. P., Kalbfleisch, J. D., & Prentice, R. L. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,248
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Multiple myeloma
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Self-citation

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 2

10.1001/archinte.135.1.147 · DOI
10.2307/2281868 · DOI · Paper page

Sorted by citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citation
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Self-citation
Multiple myeloma
Kumar, S. K., Rajkumar, S. V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,261
Self-citation
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial
Villar, J., Ferrando, C., Martínez, D., Ambrós, A., Muñoz, T., Soler, J. A., Aguilar, G., Alba, F., González-Higueras, E., Conesa, L. A., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30417-5 · Cited by 1,241
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Sonneveld, P., Avet‐Loiseau, H., Lonial, S., Usmani, S. Z., Siegel, D. S. D., Anderson, K. C., Chng, W. J., Moreau, P., Attal, M., Kyle, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-01-631200 · Cited by 949
Self-citation
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 830
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citation
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402888 · Cited by 778
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Self-citation
Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies
Chen, M., Zhao, Y., Xu, C., Wang, X., Zhang, X., & Mao, B. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3284-y · Cited by 647
Multiple myeloma
Röllig, C., Knop, S. T., & Bornhäuser, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 626
IMWG consensus on risk stratification in multiple myeloma
Chng, W. J., Dispenzieri, A. A., Chim, C. S., Fonseca, R., Goldschmidt, H., Lentzsch, S., Munshi, N. C., Palumbo, A. P., Miguel, J. F. S., Sonneveld, P., et al. (2013) · Leukemia · doi:10.1038/leu.2013.247 · Cited by 600
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
Leung, N., Bridoux, F., Hutchison, C. A., Nasr, S. H., Cockwell, P., Fermand, J., Dispenzieri, A. A., Song, K., & Kyle, R. A. (2012) · Blood · doi:10.1182/blood-2012-07-445304 · Cited by 560
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A. A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 504
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 466
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Martinez-Lopez, J., Lahuerta, J. J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M. A., Paiva, B., Weng, L., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550020 · Cited by 425
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
Snowden, J. A., Sánchez‐Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Cámara, R., Dolstra, H., Duarte, R. F., Glaß, B., Greco, R., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01691-w · Cited by 400
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
de Larrea, C. F., Kyle, R. A., Durie, B. G. M., Ludwig, H., Usmani, S. Z., Vesole, D. H., Hájek, R., Miguel, J. F. S., Sezer, O., Sonneveld, P., et al. (2012) · Leukemia · doi:10.1038/leu.2012.336 · Cited by 384
Self-citation
Multiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 373
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Hockaday, A., Jones, J. R., Kishore, B., Garg, M. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30687-9 · Cited by 354
Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
for the European Society for Blood and Marrow Transplantation (EBMT), Duarte, R. F., Labopin, M., Bader, P., Basak, G. W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0516-2 · Cited by 354
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
Sureda, A. M., Bader, P., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., Falkenburg, J. H. F., Farge, D., Gennery, A. R., Kröger, N. M., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.6 · Cited by 341
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Gay, F., Oliva, S., Petrucci, M. T., Conticello, C., Catalano, L., Corradini, P., Siniscalchi, A., Magarotto, V., Pour, L., Carella, A. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00389-7 · Cited by 318
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
Costa, L. J., Brill, I. K., Omel, J. L., Godby, K. N., Kumar, S. K., & Brown, E. E. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016002493 · Cited by 301
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
Palumbo, A. P., Bringhen, S., Kumar, S. K., Lupparelli, G., Usmani, S. Z., Waage, A., Larocca, A., van der Holt, B., Musto, P., Offidani, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70609-0 · Cited by 290
Self-citation
Frontline therapy of multiple myeloma
Moreau, P., Attal, M., & Facon, T. (2015) · Blood · doi:10.1182/blood-2014-09-568915 · Cited by 244
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0023 · Cited by 279
Self-citation
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Campagnaro, E. L., Castillo, J. J., Chandler, J. C., Costello, C. L., Efebera, Y. A., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 283
Self-citation
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Costa, L. J., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T. M., Godby, K. N., Silbermann, R. W., Dhakal, B., Bal, S., Giri, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01935 · Cited by 269
Self-citation
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors
Travis, L. B., Demark‐Wahnefried, W., Allan, J. M., Wood, M. E., & Ng, A. K. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.41 · Cited by 265
Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome
Roussel, M., Lauwers‐Cancès, V., Robillard, N., Hulin, C., Leleu, X. P., Benboubker, L., Marit, G., Moreau, P., Pegourié, B., Caillot, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8164 · Cited by 268
Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
Miguel, J. F. S., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M. H., Špıčka, I., Petrucci, M. T., Palumbo, A. P., Samoilova, O. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6180 · Cited by 263
Self-citation
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Stadtmauer, E. A., Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00685 · Cited by 259
Self-citation
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 263
Self-citation
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Gay, F., Musto, P., Rota-Scalabrini, D., Bertamini, L., Belotti, A., Galli, M., Offidani, M., Zamagni, E., Ledda, A., Grasso, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00535-0 · Cited by 258
The Diagnosis and Treatment of Multiple Myeloma
Gerecke, C., Fuhrmann, S., Strifler, S., Schmidt‐Hieber, M., Einsele, H., & Knop, S. T. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0470 · Cited by 256
Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus
Hu, Q., Qian, C., Sun, W., Wang, J., Chen, Z., Bomba, H. N., Xin, H., Shen, Q., & Gu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201603463 · Cited by 244
Current status of autologous stem cell transplantation for multiple myeloma
Hamed, R. A., Bazarbachi, A. H., Malard, F., Harousseau, J., & Mohty, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0205-9 · Cited by 256
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., Miguel, J. F. S., Ludwig, H., Schouten, H. C., Mohty, M., Dimopoulos, M. A., & Dreyling, M. H. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt297 · Cited by 242
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
Joseph, N. S., Kaufman, J. L., Dhodapkar, M. V., Hofmeister, C. C., Almaula, D. K., Heffner, L. T., Gupta, V. A., Boise, L. H., Lonial, S., & Nooka, A. K. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02515 · Cited by 238
Self-citation
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Dimopoulos, M. A., Gay, F., Schjesvold, F. H., Beksaç, M., Hájek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)33003-4 · Cited by 240
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 229
The novel mechanism of lenalidomide activity
Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Engelhardt, M. M., Terpos, E., Kleber, M., Gay, F., Wäsch, R., Morgan, G. J., Cavo, M., van de Donk, N. W. C. J., Beilhack, A., Bruno, B., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.099358 · Cited by 217
Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23810 · Cited by 215
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy
Chung, D. J., Pronschinske, K. B., Shyer, J. A., Sharma, S., Leung, S., Curran, S. A., Lesokhin, A. M., Devlin, S. M., Giralt, S., & Young, J. W. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0055 · Cited by 211
Self-citation
Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
Rosenblatt, J. M., Avivi, I. M., Vasir, B., Uhl, L., Munshi, N. C., Katz, T., Dey, B. R., Somaiya, P., Mills, H., Campigotto, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0282 · Cited by 207
Self-citation
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
Palumbo, A. P., Bringhen, S., Larocca, A., Rossi, D., Raimondo, F. D., Magarotto, V., Patriarca, F. F., Levi, A., Benevolo, G., Vincelli, I. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0023 · Cited by 207
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J. J., Chandler, J. C., Costello, C. L., Faiman, M., Fung, H. C. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0002 · Cited by 203
Self-citation
Proteasome Inhibitors for the Treatment of Multiple Myeloma
Ito, S. (2020) · Cancers · doi:10.3390/cancers12020265 · Cited by 210
International Myeloma Working Group recommendations for global myeloma care
Ludwig, H., Miguel, J. F. S., Dimopoulos, M. A., Palumbo, A. P., García‐Sánz, R., Powles, R., Lentzsch, S., Chen, W. M., Hou, J., Jurczyszyn, A. J., et al. (2013) · Leukemia · doi:10.1038/leu.2013.293 · Cited by 202
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
Gahrton, G., Iacobelli, S., Björkstrand, B., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Carella, A. M., Beksaç, M., et al. (2013) · Blood · doi:10.1182/blood-2012-11-469452 · Cited by 192
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Moreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Zweegman, S., Caillon, H., Caillot, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00428-9 · Cited by 184
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
Costa, L. J., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T. M., Godby, K. N., Silbermann, R. W., Dhakal, B., Bal, S., Giri, S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00236-3 · Cited by 178
Self-citation
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
Holstein, S. A., Jung, S., Richardson, P. G. G., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30140-0 · Cited by 178
Self-citation
Progress and Paradigms in Multiple Myeloma
Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0625 · Cited by 173
Self-citation
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
Mouhieddine, T. H., Sperling, A. S., Redd, R. A., Park, J., Leventhal, M. J., Gibson, C. J., Manier, S., Nassar, A. H., Capelletti, M., Huynh, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16805-5 · Cited by 176
Self-citation
Association of response endpoints with survival outcomes in multiple myeloma
Lonial, S., & Anderson, K. C. (2014) · Leukemia · doi:10.1038/leu.2013.220 · Cited by 162
Self-citation
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
Kumar, S. K., Callander, N. S., Hillengaß, J., Liedtke, M., Baljević, M., Campagnaro, E. L., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0049 · Cited by 161
Self-citation
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
Landgren, O., & Iskander, K. S. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12590 · Cited by 160
Myeloma today: Disease definitions and treatment advances
Rajkumar, S. V. (2015) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 163
Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2013) · American Journal of Hematology · doi:10.1002/ajh.23390 · Cited by 158
Emerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 160
Treatment options for relapsed and refractory multiple myeloma
Nooka, A. K., Kastritis, E., Dimopoulos, M. A., & Lonial, S. (2015) · Blood · doi:10.1182/blood-2014-11-568923 · Cited by 157
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
Richardson, P. G. G., Jagannath, S., Moreau, P., Jakubowiak, A. J., Raab, M. S., Facon, T. T. F., Vij, R., White, D. J., Reece, D. E., Benboubker, L., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00197-0 · Cited by 156
Self-citation
Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
Morgan, G. J., Davies, F. E., Gregory, W. M., Bell, S. E., Szubert, A. J., Cook, G., Drayson, M. T., Owen, R. G., Ross, F. M., Jackson, G. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3211 · Cited by 156
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
Musto, P., Anderson, K. C., Attal, M., Richardson, P. G. G., Badros, A., Hou, J., Comenzo, R. L., Du, J., Durie, B. G. M., Miguel, J. F. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw606 · Cited by 153
Self-citation
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
Cook, G., Williams, C. D., Brown, J. M., Cairns, D. A., Cavenagh, J. D., Snowden, J. A., Ashcroft, A. J., Fletcher, M., Parrish, C., Yong, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70245-1 · Cited by 152
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Palumbo, A., Gay, F., Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., Nagler, A., Petrucci, M. T., Hajek, R., Pezzatti, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2466 · Cited by 150
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Cook, G., Ashcroft, A. J., Cairns, D. A., Williams, C. D., Brown, J. M., Cavenagh, J. D., Snowden, J. A., Parrish, C., Yong, K., Cavet, J., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30049-7 · Cited by 149
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
Stewart, A. K., Trudel, S., Bahlis, N. J., White, D. J., Sabry, W., Belch, A. R., Reiman, T., Roy, J., Shustik, C., Kovacs, M. J., et al. (2013) · Blood · doi:10.1182/blood-2012-09-451872 · Cited by 142
Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea
Gerber, D. E., & Schiller, J. H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7459 · Cited by 141
Therapy for Relapsed Multiple Myeloma
Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A. A., Fonseca, R., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Kapoor, P., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.003 · Cited by 144
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Moreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Zweegman, S., Caillon, H., Caillot, D., Avet‐Loiseau, H., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00282-1 · Cited by 145
Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study
Polizzotto, M. N., Uldrick, T. S., Wyvill, K. M., Aleman, K., Peer, C. J., Bevans, M., Sereti, I., Maldarelli, F., Whitby, D., Marshall, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.3812 · Cited by 138
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Multiple myeloma: the (r)evolution of current therapy and a glance into future
Gullà, A., & Anderson, K. C. (2020) · Haematologica · doi:10.3324/haematol.2020.247015 · Cited by 143
Self-citation
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
Mellqvist, U., Gimsing, P., Hjertner, Ø., Lenhoff, S., Laane, E., Remes, K., Steingrímsdóttir, H., Abildgaard, N., Ahlberg, L., Blimark, C. H., et al. (2013) · Blood · doi:10.1182/blood-2012-11-464503 · Cited by 138
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
Bjorklund, C. C., Baladandayuthapani, V, Lin, H. Y., Jones, R. J., Kuiatse, I., Wang, H., Yang, J., Shah, J. J., Thomas, S. K., Wang, M., et al. (2014) · Leukemia · doi:10.1038/leu.2013.174 · Cited by 131
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
Avet‐Loiseau, H., Ludwig, H., Landgren, O., Paiva, B., Morris, C., Yang, H., Zhou, K., Ro, S. K., & Mateos, M. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.622 · Cited by 133
Targeting MYC in multiple myeloma
Jovanović, K., Roche‐Lestienne, C., Ghobrial, I. M., Facon, T. T. F., Quesnel, B., & Manier, S. (2018) · Leukemia · doi:10.1038/s41375-018-0036-x · Cited by 133
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
Scheid, C., Sonneveld, P., Schmidt‐Wolf, I. G. H., van der Holt, B., Jarari, L. E., Bertsch, U., Salwender, H. J., Zweegman, S., Blau, I. W., Vellenga, E., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.087585 · Cited by 127
Functional Roles of the E3 Ubiquitin Ligase UBR5 in Cancer
Shearer, R. F., Iconomou, M., Watts, C. K. W., & Saunders, D. N. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0383 · Cited by 125
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
Gay, F., Engelhardt, M. M., Terpos, E., Wäsch, R., Giaccone, L., Auner, H. W., Caers, J., Gramatzki, M., van de Donk, N. W. C. J., Oliva, S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.174573 · Cited by 126
Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
Rapoport, A. P., Aqui, N. A., Stadtmauer, E. A., Vogl, D. T., Xu, Y. Y., Kalos, M. D., Cai, L., Fang, H., Weiss, B. M., Badros, A. Z., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2817 · Cited by 123
Self-citation
Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation
Shah, N., Callander, N. S., Ganguly, S., Gul, Z., Hamadani, M., Costa, L. J., Sengsayadeth, S. M., Abidi, M. H., Hari, P., Mohty, M., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.03.002 · Cited by 127
Self-citation
Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration
Hilal, T., Sonbol, M. B., & Prasad, V. K. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0167 · Cited by 123
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
Gonsalves, W. I., Buadi, F. K., Ailawadhi, S., Bergsagel, P. L., Khan, A. A. C., Dingli, D., Dispenzieri, A. A., Fonseca, R., Hayman, S. R., Kapoor, P., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0264-8 · Cited by 119
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
Dimopoulos, M. A., Jakubowiak, A. J., McCarthy, P. L., Orlowski, R. Z., Attal, M., Bladé, J., Goldschmidt, H., Weisel, K. C., Ramasamy, K., Zweegman, S., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0273-x · Cited by 116
Self-citation
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma
Brioli, A., Melchor, L., Cavo, M., & Morgan, G. J. (2014) · British Journal of Haematology · doi:10.1111/bjh.12805 · Cited by 116
Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age
McCarthy, P. L., Hahn, T., Hassebroek, A. M., Bredeson, C., Gajewski, J., Hale, G. A., Isola, L. M., Lazarus, H. M., Lee, S. J., LeMaistre, C. F., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.04.027 · Cited by 113
Self-citation
Review of health-related quality of life data in multiple myeloma patients treated with novel agents
Sonneveld, P., Verelst, S. G. R., Lewis, P., Gray‐Schopfer, V. C., Hutchings, A., Nixon, A., & Petrucci, M. T. (2013) · Leukemia · doi:10.1038/leu.2013.185 · Cited by 110

Authors: McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R. T., Gabriel, D. A., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Anderson, K. C., & Linker, C.
Affiliations: Roswell Park Comprehensive Cancer Center (US)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Duke University (US)
Memorial Sloan Kettering Cancer Center (US)
Dana-Farber Cancer Institute (US)
Abramson Cancer Center (US)
University of Minnesota Medical Center (US)
Washington University in St. Louis (US)
University of Florida (US)
University of Wisconsin–Madison (US)
State University of New York (US)
Mount Sinai Hospital (US)
Oregon Health & Science University (US)
University of North Carolina at Chapel Hill (US)
BMT Group (United States) (US)
University of California, San Francisco (US)
The University of Texas MD Anderson Cancer Center (US)
University of Chicago (US)
University of Chicago Medical Center (US)
Medical College of Wisconsin (US)
ORCID: McCarthy, Philip L.
Owzar, Kouros
Hofmeister, Craig C.
Hassoun, Hani
Richardson, Paul G.
Giralt, Sergio
Stadtmauer, Edward A.
Weisdorf, Daniel J.
Vij, Ravi
Moreb, Jan S.
Callander, Natalie Scott
Gentile, Teresa
Isola, Luis
Maziarz, Richard T.
Landau, Heather
Martin, Thomas
Qazilbash, Muzaffar H.
McClune, Brian
Jiang, Chen
Bennett, Elizabeth
Kelly, Michael
Rosenbaum, Cara
Hari, Parameswaran
Pasquini, Marcelo C.
Horowitz, Mary M.
Devine, Steven M.
Anderson, Kenneth C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-05-10
Volume: 366
Issue: 19
Pages: 1770-1781
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1114083
PMC: PMC3744390
OpenAlex: W2125721471
Semantic Scholar: b20a8f57aae32a45c1804976b107b4ba1609688f
Cited by: 1,147
References: 42
Citations by year: 2026: 28 · 2025: 30 · 2024: 40 · 2023: 40 · 2022: 51 · 2021: 74 · 2020: 81 · 2019: 70 · 2018: 82 · 2017: 104 · 2016: 107 · 2015: 100 · 2014: 113 · 2013: 144 · 2012: 81
FWCI: 93.26
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
Funders: National Heart, Lung, and Blood Institute (U10HL069334, U10HL069301, U10HL069348, U10HL109526, U01HL069294, U10HL069294, U10HL069330, U10HL069315, U10HL069290, U10HL069286, UG1HL069286, UG1HL069315)
National Cancer Institute (U10CA033601, P50CA100707, U10CA031946, U10CA021115, U24CA076518)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords: lenalidomide, multiple myeloma, autologous stem cell transplantation, maintenance therapy, time to progression, overall survival, secondary malignancies, hematologic adverse events, drug toxicity
MeSH terms: Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks